Evidence map›Paper›PMID 38002722›Full record

ArticleJournal of clinical medicine2023

Combined Hormonal Contraception during Breastfeeding-A Survey of Physician's Recommendations.

Lior Segev, Gideon Weitzman, Goldie Katz-Samson, Abraham O Samson, Guy Shrem, Naama Srebnik

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Expanding access to postpartum contraception.Current opinion in obstetrics & gynecology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Lior SegevAzrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Gideon WeitzmanPUAH Institute: Fertility, Medicine, Halacha, Jerusalem 9547735, Israel.
Goldie Katz-SamsonNishmat: The Jeanie Schottenstein Center for Advanced Torah Study for Women, Jerusalem 9328249, Israel.
Abraham O SamsonAzrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.ORCID 0000-0001-7436-3515
Guy ShremIVF Unit, Department of Obstetrics and Gynecology, Kaplan Medical Center, Rehovot 7610001, Israel.ORCID 0000-0002-3825-3965
Naama SrebnikFaculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel.ORCID 0000-0003-0488-9313
Bar-Ilan University · ILHebrew University of Jerusalem · ILKaplan Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Until breastfeeding is established, progesterone-only pill (POP) use is preferable over combined hormonal contraception (CHC), as the latter potentially reduces milk production. Yet, POPs are often associated with breakthrough bleeding (BTB), and irregular spotting is often a reason for their cessation. Conversely, CHC is less associated with BTB but is not usually prescribed, even if breastfeeding has been established, despite its verified safety profile. Here, we surveyed physicians' perception of CHC safety during breastfeeding through an online questionnaire (N = 112). Physicians were asked if they would prescribe CHC to a woman three months postpartum, breastfeeding fully, and suffering from BTB while using POPs. Half of the physicians responded they would, 28% would not until six months postpartum, while 14% would not during breastfeeding. Of the physicians that would prescribe CHC, 58% would without any reservation, 24% would only after discussing milk reduction with the patient, 9% would use a pill with a lower hormonal dose, and 9% would only prescribe CHC 3 months postpartum. The main risk associated with CHC during breastfeeding, as perceived by physicians, is a potential decrease in breast milk production (88%). While some physicians consider CHC unsafe during breastfeeding, most health organizations consider CHC compatible with breastfeeding 5-6 weeks after birth. Thus, there is a gap in the attitude and knowledge of physicians about the safety profile of CHC, and only half acknowledge that the risk of BTB justifies the use of CHC instead of POPs while breastfeeding three months postpartum. We highlight the importance of physician's education, advocate CHC breastfeeding compatibility if breastfeeding has been established (i.e., 30 days postpartum), and underline the importance of discussing the option of CHC with patients in case POPs have unwanted side effects.

Indexed as

breastfeedingcombined hormonal contraceptionprogesterone-only pill

Identifiers

PMID38002722
PMCPMC10671995
OpenAlexW4388694191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.